← Leaderboards
Mark I Greene
University Of Pennsylvania
$18,808,015
Attributed
$19,029,390
Total exposure
17
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$31,386,333 · 19
By mechanism
P01$14,348,158 · 6
R01$13,054,800 · 8
T32$1,746,097 · 2
U01$1,394,528 · 1
R21$442,750 · 1
R56$400,000 · 1
Top collaborators
- Taku Kambayashi2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- John J Cebra$3,084,734
- Felice Elefant$4,943,868
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsLeadReceptorComplexIn VitroMediatingIn VivoProteinsSignal TransductionPatternAntibodiesDesignMalignant - DescriptorLinkPhosphotransferasesAffectImmuneTumorMonitorPhenotypeDimerCell TransformationBaseNeoplastic Cell
Grant awards (80)
Immunologic aspects of targeted therapy of erbB tumors$360,922
R01 · FY2022 · CA · contact PI
Immunologic aspects of targeted therapy of erbB tumors$368,288
R01 · FY2021 · CA · contact PI
Immunologic aspects of targeted therapy of erbB tumors$368,288
R01 · FY2020 · CA · contact PI
Immunologic aspects of targeted therapy of erbB tumors$357,238
R01 · FY2019 · CA · contact PI
The Role of Post-translational Modifier PRMT5 in Regulatory T cell Development and Function$241,500
R21 · FY2019 · AI · contact PI
Immunologic aspects of targeted therapy of erbB tumors$368,288
R01 · FY2018 · CA · contact PI
The Role of Post-translational Modifier PRMT5 in Regulatory T cell Development and Function$201,250
R21 · FY2018 · AI · contact PI
Carbohydrate Antigenic Biomarkers for Epithelial Cancers$444,838
U01 · FY2016 · CA · contact PI
Carbohydrate Antigenic Biomarkers for Epithelial Cancers$453,721
U01 · FY2015 · CA · contact PI
Inhibition of heteromeric erbB kinases$332,311
R01 · FY2015 · CA · contact PI
Receptor mediated breast cancer therapy$253,793
R01 · FY2015 · CA · contact PI
Carbohydrate Antigenic Biomarkers for Epithelial Cancers$495,969
U01 · FY2014 · CA · contact PI
Early T Lineage Progenitors$400,000
R56 · FY2014 · AI · contact PI
Migration of hematopoietic progenitors to the thymus$380,728
R01 · FY2014 · HL · contact PI
Inhibition of heteromeric erbB kinases$322,342
R01 · FY2014 · CA · contact PI
Receptor mediated breast cancer therapy$246,179
R01 · FY2014 · CA · contact PI
Inhibition of heteromeric erbB kinases$314,887
R01 · FY2013 · CA · contact PI
Receptor mediated breast cancer therapy$238,565
R01 · FY2013 · CA · contact PI
Immune chemistry and therapeutic features of FOXP3$1,380,336
P01 · FY2012 · AI · contact PI
Inhibition of heteromeric erbB kinases$338,474
R01 · FY2012 · CA · contact PI
FOXP3 and immune regulation$294,897
P01 · FY2012 · AI · contact PI
Receptor mediated breast cancer therapy$253,793
R01 · FY2012 · CA · contact PI
Administrative Core$48,634
P01 · FY2012 · AI · contact PI
Immune chemistry and therapeutic features of FOXP3$1,476,727
P01 · FY2011 · AI · contact PI
Inhibition of heteromeric erbB kinases$338,474
R01 · FY2011 · CA · contact PI
FOXP3 and immune regulation$299,159
P01 · FY2011 · AI · contact PI
Receptor mediated breast cancer therapy$268,793
R01 · FY2011 · CA · contact PI
Immunobiology of p185 receptor$261,108
R01 · FY2011 · CA · contact PI
Administrative Core$96,042
P01 · FY2011 · AI · contact PI
Immune chemistry and therapeutic features of FOXP3$1,400,493
P01 · FY2010 · AI · contact PI
FOXP3 and immune regulation$278,881
P01 · FY2010 · AI · contact PI
Immunobiology of p185 receptor$269,183
R01 · FY2010 · CA · contact PI
Administrative Core$89,944
P01 · FY2010 · AI · contact PI
Immune chemistry and therapeutic features of FOXP3$1,403,522
P01 · FY2009 · AI · contact PI
FOXP3 and immune regulation$274,707
P01 · FY2009 · AI · contact PI
Immunobiology of p185 receptor$269,183
R01 · FY2009 · CA · contact PI
Administrative Core$89,016
P01 · FY2009 · AI · contact PI
Immune chemistry and therapeutic features of FOXP3$1,416,324
P01 · FY2008 · AI · contact PI
Immunobiology of p185 receptor$269,183
R01 · FY2008 · CA · contact PI
FOXP3 and immune regulation$267,185
P01 · FY2008 · AI · contact PI
Receptor mediated breast cancer therapy$249,851
R01 · FY2008 · CA · contact PI
Administrative Core$90,458
P01 · FY2008 · AI · contact PI
Receptor-mediated effects on oligodendrocyte phenotype and disease$356,931
R01 · FY2007 · NS · contact PI
Training in Cancer Immunopathobiology$300,884
T32 · FY2007 · CA · contact PI
Viral receptors of the visual nervous system$270,394
R01 · FY2007 · NS · contact PI
Immunobiology of p185 receptor$263,002
R01 · FY2007 · CA · contact PI
Receptor mediated breast cancer therapy$249,851
R01 · FY2007 · CA · contact PI
Receptor mediated efffects on oligodendrocyte phenotype$367,592
R01 · FY2006 · NS · contact PI
Viral receptors of the visual nervous system$278,699
R01 · FY2006 · NS · contact PI
Training in Cancer Immunopathobiology$277,688
T32 · FY2006 · CA · contact PI
Immunobiology of p185 receptor$270,857
R01 · FY2006 · CA · contact PI
Receptor mediated breast cancer therapy$257,314
R01 · FY2006 · CA · contact PI
Novel approaches to cancer therapy$1,376,721
P01 · FY2005 · CA
Receptor mediated efffects on oligodendrocyte phenotype$376,438
R01 · FY2005 · NS
Viral receptors of the visual nervous system$292,887
R01 · FY2005 · NS
Immunobiology of p185 receptor$277,375
R01 · FY2005 · CA
Training in Cancer Immunopathobiology$266,559
T32 · FY2005 · CA
Receptor mediated breast cancer therapy$263,506
R01 · FY2005 · CA
Novel approaches to cancer therapy$1,333,893
P01 · FY2004 · CA
Receptor mediated efffects on oligodendrocyte phenotype$376,438
R01 · FY2004 · NS
Training in Cancer Immunopathobiology$360,343
T32 · FY2004 · CA
Viral receptors of the visual nervous system$293,225
R01 · FY2004 · NS
Immunobiology of p185 receptor$277,375
R01 · FY2004 · CA
Receptor mediated breast cancer therapy$263,506
R01 · FY2004 · CA
Novel approaches to cancer therapy$1,282,639
P01 · FY2003 · CA
Receptor-mediated effects on oligodendrocyte phenotype$376,438
R01 · FY2003 · NS
Training in Cancer Immunopathobiology$355,289
T32 · FY2003 · CA
Immunobiology of p185 receptor$277,375
R01 · FY2003 · CA
RECEPTOR MEDIATED BREAST CANCER THERAPY$267,865
R01 · FY2003 · CA
Novel approaches to cancer therapy$1,286,288
P01 · FY2002 · CA
RECEPTOR MEDIATED BREAST CANCER THERAPY$267,865
R01 · FY2002 · CA
CORE--STRUCTURAL$0
P01 · FY2002 · CA
6C10 T CELL SUBSET IN TOLERANCE$0
P01 · FY2002 · AI
RECEPTOR MEDIATED BREAST CANCER THERAPY$267,865
R01 · FY2001 · CA
IMMUNOBIOLOGY OF ANTIRECEPTOR RECEPTOR INTERACTIONS$36,333
R01 · FY2001 · EY
6C10 T CELL SUBSET IN TOLERANCE$0
P01 · FY2001 · AI
IMMUNOBIOLOGY OF P185 RECEPTOR$208,674
R01 · FY2000 · CA
IMMUNOBIOLOGY OF ANTIRECEPTOR RECEPTOR INTERACTIONS$187,124
R01 · FY2000 · EY
TRAINING PROGRAM IN IMMUNOBIOLOGY OF THE EYE$185,334
T32 · FY2000 · EY
6C10 T CELL SUBSET IN TOLERANCE$162,292
P01 · FY2000 · AI